Comparison of the effects of sparsentan and ambrisentan

Sparsentan is a dual-action drug that inhibits both non-tyrosine kinase(TYK2) and angiotensin II type 1 receptor (AT1). This dual inhibitory effect allows spasentan to suppress immune responses and reduce kidney damage through two different pathways.

Ambrisentan is a monoclonal antibody that reduces inflammatory responses and kidney damage mainly by targeting and blocking the pro-inflammatory cytokine interleukin-1β(IL-1β).

Sparsentan reduces the symptoms and damage of immunoglobulinA nephropathy by reducing the activity of immune cells and inhibiting fibrosis in the kidney. Its efficacy has been verified in clinical trials, significantly reducing proteinuria levels and also having a positive impact on the improvement of kidney function.

Ambrisentan reduces the inflammatory response by inhibitingIL-1β, thereby reducing kidney damage and symptoms. However, there are relatively few specific data on the effectiveness of ambrisentan in reducing proteinuria and protecting renal function.

In clinical trials, sparsentan has shown significant efficacy, particularly in reducing proteinuria and improving kidney function. A clinical trial of sparsentan showed that it significantly reduced proteinuria levels compared with placebo.

Although ambrisentan has also shown some efficacy, especially in reducing inflammatory responses, there are relatively few data on its ability to reduce proteinuria and protect renal function compared with sparsentan.

There are significant differences in pharmacological characteristics, therapeutic mechanisms and clinical applications between sparsentan and ambrisentan. Sparsentan has shown significant efficacy in reducing proteinuria and improving renal function through its dual inhibitory effect, while ambrisentan works mainly by inhibiting the inflammatory response. The specific choice of drug should be determined based on the patient's specific situation and the doctor's advice.